Quick Answer
Can-Fite BioPharma Ltd. reported Total Revenue of $405.0 thousand for fiscal year 2025.
Can-Fite BioPharma Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $405.0K -39.9% |
$674.0K -9.3% |
$743.0K -8.3% |
$810.0K -5.0% |
$853.0K +11.8% |
$763.0K -62.5% |
| Net Income | -$9.83M -24.7% |
-$7.88M -3.2% |
-$7.63M +25.0% |
-$10.17M +19.4% |
-$12.62M +12.7% |
-$14.44M -14.4% |
| Diluted EPS | -$5.97 +45.0% |
-$10.86 +39.4% |
-$17.92 -179100.0% |
-$0.01 +66.7% |
-$0.03 +25.0% |
-$0.04 |
| Total Assets | $9.51M +4.3% |
$9.12M -8.7% |
$9.99M +7.6% |
$9.28M -54.2% |
$20.25M +112.7% |
$9.52M +16.5% |
| Cash and Equivalents | $5.53M +14.6% |
$4.83M +12.8% |
$4.28M +43.7% |
$2.98M -32.2% |
$4.39M -46.9% |
$8.27M +206.6% |
| Stockholders Equity | $5.59M +2.9% |
$5.44M -12.9% |
$6.24M +39.6% |
$4.47M -68.9% |
$14.38M +136.8% |
$6.07M +148.7% |
| R&D Expense | $6.69M +16.3% |
$5.76M -3.8% |
$5.98M -22.9% |
$7.76M -21.2% |
$9.85M -17.6% |
$11.95M +8.9% |
| Operating Income | -$9.95M -22.4% |
-$8.13M +0.8% |
-$8.20M +18.8% |
-$10.10M +21.4% |
-$12.84M +9.2% |
-$14.14M -17.8% |
| Shares Outstanding | 2.62M +163.3% |
994,394 -99.9% |
1.36B +66.7% |
815.75M +0.0% |
815.75M +75.9% |
463.77M +284.4% |
- Can-Fite BioPharma Ltd. reported Total Revenue of $405.0 thousand for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed a decrease of -39.9% in Total Revenue compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Net Income of -$9.83 million for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed a decrease of -24.7% in Net Income compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Diluted EPS of $5.97 per share (loss) for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed an increase of +45.0% in Diluted EPS compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Total Assets of $9.51 million for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed an increase of +4.3% in Total Assets compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Cash and Equivalents of $5.53 million for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed an increase of +14.6% in Cash and Equivalents compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Stockholders Equity of $5.59 million for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed an increase of +2.9% in Stockholders Equity compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported R&D Expense of $6.69 million for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed an increase of +16.3% in R&D Expense compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Operating Income of -$9.95 million for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed a decrease of -22.4% in Operating Income compared to the prior fiscal year.
- Can-Fite BioPharma Ltd. reported Shares Outstanding of 2.62 million shares for fiscal year 2025.
- Can-Fite BioPharma Ltd. showed an increase of +163.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: